Hypertension is best defined as the level of blood pressure, there are no randomized controlled trial data. Epidemiological data suggest that levels of pressure above which treatment does more good than harm. This information comes from the results of ran-125 mmHg should be achieved,7 but the guidelines are more conservative, suggesting <140 mmHg.1,2 domized controlled trials, i.e. the evidence base. However, we do not know the level of blood pressure
For diastolic blood pressure, the Hypertension Optimum Treatment (HOT) trial randomized patients at which treatment fails to confer an overall benefit. Such a level is predicted to exist, as at lower levels of to achieve a diastolic blood pressure of <90 mmHg, <85 mmHg or <80 mmHg.8 In the event, the blood pressure, few gain by having cardiovascular events prevented yet all are at risk of the adverse achieved blood pressures averaged 85.2, 83.2 and 81.1 mmHg for the three groups, respectively. effects of treatment. At the beginning of 2000, we know that at most ages it is worth treating a systolic Cardiac and stroke events did not differ with statistical significance between the three groups. The epiblood pressure Á160 mmHg and/or a diastolic blood pressure Á90 mmHg. This has not prevented specudemiological data suggest that diastolic pressure should not be lowered below 85 mmHg, because of lation that treatment should be started at say, a systolic pressure of 140-159 mmHg.1,2 Nevertheless the J-shaped curve where ischaemic heart disease (IHD) mortality increases with a treated diastolic caution must be expressed that adverse effects may outweigh advantages in certain groups, for example blood pressure of ∏85 mmHg. However, the HOT trial does not support this and in the Systolic the very elderly (>80 years) and those whose blood pressure is high when lying but low on standing. The Hypertension in the Elderly Program (SHEP) trial, cardiac deaths were reduced when diastolic pressure same may apply to those with a high blood pressure when first seen but normal pressures thereafter; was lowered from an average of 77 mmHg to 68 mmHg, albeit in the presence of a high systolic although transient hypertension, at least in men, still confers an excess cardiovascular risk.3 Obviously we pressure.4 Most researchers have concluded that the J-shaped increase in mortality at lower pressure is not should consider the over-80s further, assess blood pressure in the standing position, and determine the produced by the pressure, rather that the lower pressure is induced by coronary disease.9 sustained level of blood pressure.
At age 65-79 years, experimental evidence sugIn the HOT trial, systolic pressure was reduced from an average of 170 mmHg to 140-144 mmHg. In gests that a sustained systolic pressure Á160 mmHg should be treated irrespective of diastolic blood presthe European Working Party on High blood Pressure in the Elderly (EWPHE), SHEP and Systolic sure.4,5 It is also probable (but not proven) that a diastolic pressure of Á90 mmHg should be treated Hypertension in Europe (Syst-Eur) trials systolic pressures were reduced from means of 183, 170 and irrespective of systolic pressure.6 The pressure should be measured at least three times on separate occa-174 mmHg, to 149, 144 and 151 mmHg, respectively.4-6 In these trials, the goal blood pressure was sions over a period of time. The period of time should be at least 2 months, to agree with the evidence from 140-160 mmHg (not 125 mmHg!) and even so about 30-50% of patients failed to achieve goal blood presthe trials, and the blood pressure should be taken in the sitting position but with a standing systolic pressure. Moreover, this effect required two or more antihypertensive drugs in more than 40% of patients. We sure of at least 140 mmHg.5 Thus we have an evidence base for treatment in subjects under age 80, but must conclude that with today's pharmacological treatments, we are unlikely to reach 'low' goal having decided on 'treatment', what should this be and what constitutes 'control' of hypertension?
pressures. Side-effects must be avoided, for example postural hypotension. The latter may be a greater Unlike the level of pressure at which we should treat, the level of blood pressure that we should problem in the elderly and be compounded by postprandial hypotension. These side-effects will certainly achieve with treatment is unknown. For systolic limit the numbers achieving goal blood pressure, and ASCOT, but in the meantime the drug employed would not appear very important. Obviously there even if assessed in the standing position, and may increase the default rates on treatment. In theory, are contra-indications, and these must be adhered to, similarly side-effects and quality-of-life issues may we may strive to lower systolic pressure to below 125 mmHg and diastolic pressure to below determine choice of drug. Some drugs are popularly used in certain circumstances, for example ACE 80 mmHg but in practice, especially in the elderly, we are likely to be disappointed. A possible praginhibitors in diabetics. However, low-dose diuretics are inexpensive and successful, even in diabetic matic rule, valid only at the time of writing, is that the goal blood pressure in the elderly should be 'a patients,15 as are calcium-channel blockers.16 The important consideration is to avoid specific drugs in standing systolic pressure <140 mmHg and diastolic <80 mmHg'. certain conditions, e.g. beta blockers in asthmatics, calcium channel blockers in heart failure, diuretics in The evidence base for non-pharmacological treatments in the very elderly is very sparse, but unless the gout, and find the drug or combination of drugs that achieve goal blood pressure. patient consumes large amounts of alcohol and stops, is grossly overweight and loses weight, or greatly
In the very elderly, over the age of 80, the picture is more confusing. First the epidemiology suggest that reduces sodium intake, large reductions in pressure are unlikely. My personal view is that smoking must the higher the blood pressure, the lower the mortality,17 and second, there is currently no evidence base be stopped and that may require firm advice, nicotine patches or inhaler (the gum is difficult with false from randomized trials to support treatment. The epidemiological findings, for the elderly population as a teeth), hypnotherapy or acupuncture. Ignore comments such as 'grandfather's sole remaining pleasure' whole, appear well substantiated, but this inverse relationship between blood pressure and mortality and 'he will not live long enough to benefit'-if his expectation of life is so short, we are not going to may simply be an extension of the J-shaped curve. In the over-80s, subjects with a low blood pressure may treat his hypertension! Having dealt with smoking, the concepts of abstinence from alcohol, weight loss, not only include those with a fibrotic myocardium following myocardial infarction, but those who have sodium reduction and exercise may be introduced but expect to give drug treatment in the end. After all lost weight through cancer, dementia and other illnesses. No surprise, perhaps, that those with a high the rule of halves or (hopefully) thirds is still with us; if one third of hypertensives are unknown, one third blood pressure are the fittest and survive well. Nevertheless, we need to know whether, with treatof these are untreated and one third of these uncontrolled, then only 30% have good blood pressure ment, these fit subjects will live even longer. No trial, with the exception of the Hypertension in the Very control. We must be careful not to frighten patients away with difficult diets (low salt plus low sugar plus Elderly (HYVET) pilot trial18 has been specifically targeted at the over-80s, however, a meta-analysis of low fat plus high fibre) and to avoid side-effects if possible.
subjects over the age of 80 entered into other trials showed some intriguing results. Strokes (fatal plus Assuming we have agreed on a goal pressure, how is it to be achieved? The selection of an antinon-fatal) appeared to be reduced by active treatment, whereas total mortality tended to be hypertensive drug has had more to do with marketing than science, but a new generation of trials have been increased.19 As discussed, there must be a blood pressure, or age (or some combination of pressure and designed that compare the different drugs in terms of morbidity and mortality outcomes. It is expected that age) that is not worth treating because the adverse effects outweigh the benefits. The problem of providthese trials will provide valuable information. The forerunners of the modern trials comparing active ing evidence for or against treatment is being addressed in the main HYVET trial. In the meantime, treatments were the Medical Research Council (MRC) trials where patients were randomized 25151 to plawhom shall we treat? Firstly, severe hypertension is excluded from the HYVET trial, and systolic pressure cebo, diuretic and beta-blocker treatment.10,11 In the MRC trial in the elderly, patients treated with a betaof Á200 mmHg or diastolic pressure Á110 mmHg deserve treatment in the absence of an evidence base. blocker fared badly,11 leading to the suggestion that beta-blockers should be avoided in this age
Others exclusions indicate whom to treat: those with any degree of heart failure, angina, renal failure or group.12,13 However the STOP (Swedish Trial in Old Patients)-hypertension-2 trial has recently reported (rarely) evidence of accelerated hypertension. For other patients, if you treat them they may avoid a in which beta-blocker±diuretic treatment was compared with calcium channel blocker±beta stroke but not necessarily live any longer. The optimist may assume that, as all placebo-controlled trials in blocker and angiotensin-converting-enzyme (ACE) inhibitor±diuretic treatment.14 No disadvantage was hypertension have shown overall benefit, so will trials in the very elderly; The pessimist, always wrong in found for a beta-blocker. Two further trials are in progress to compare different treatments, ALLHAT the past, may not wish to provide pharmacological blood pressure lowering and low-dose aspirin in patients intervention to fit survivors, many who have had mild 
